Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Baptist Vermorken

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Current Opinion in Oncology|April 18, 2009
Human papillomavirus-related head and neck tumors: clinical and research implicationAmanda Psyrri, Panagiotis Gouveris, Jan Baptist Vermorken
Frontiers in Oncology|March 19, 2025
Systemic therapy for laryngeal carcinomaThorsten Fuereder, Florian Kocher, Jan Baptist Vermorken
Patient Education and Counseling|March 15, 2006
General practitioners' perception of risk factors for cervical cancer development: consequences for patient educationMarc F D Baay, Veronique Verhoeven, Lieve Peremans, et al.
Cancers|December 23, 2022
Co-Targeting the EGFR and PI3K/Akt Pathway to Overcome Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma: What about Autophagy?Hannah Zaryouh, Jinthe Van Loenhout, Marc Peeters, et al.
Clinical Therapeutics|October 22, 2019
Cost-effectiveness of Molecular Profile Patient Selection for First-line Treatment of Recurrent/Metastatic Head and Neck CancerCarla Rognoni, Silvana Quaglini, Jan Baptist Vermorken, et al.
Medicinal Research Reviews|April 30, 2021
Recent insights in the PI3K/Akt pathway as a promising therapeutic target in combination with EGFR-targeting agents to treat head and neck squamous cell carcinomaHannah Zaryouh, Ines De Pauw, Hasan Baysal, et al.
Frontiers in Oncology|September 27, 2021
The Role of Akt in Acquired Cetuximab Resistant Head and Neck Squamous Cell Carcinoma: An <i>In Vitro</i> Study on a Novel Combination StrategyHannah Zaryouh, Ines De Pauw, Hasan Baysal, et al.
Frontiers in Immunology|September 24, 2021
The Right Partner in Crime: Unlocking the Potential of the Anti-EGFR Antibody Cetuximab <i>via</i> Combination With Natural Killer Cell Chartering Immunotherapeutic StrategiesHasan Baysal, Ines De Pauw, Hannah Zaryouh, et al.
Cancers|January 18, 2019
Overcoming Intrinsic and Acquired Cetuximab Resistance in RAS Wild-Type Colorectal Cancer: An In Vitro Study on the Expression of HER Receptors and the Potential of AfatinibInes De Pauw, Filip Lardon, Jolien Van den Bossche, et al.
Molecular Oncology|April 1, 2018
Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell linesInes De Pauw, Filip Lardon, Jolien Van den Bossche, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Current Opinion in Oncology|April 18, 2009
Human papillomavirus-related head and neck tumors: clinical and research implicationAmanda Psyrri, Panagiotis Gouveris, Jan Baptist Vermorken
Frontiers in Oncology|March 19, 2025
Systemic therapy for laryngeal carcinomaThorsten Fuereder, Florian Kocher, Jan Baptist Vermorken
Patient Education and Counseling|March 15, 2006
General practitioners' perception of risk factors for cervical cancer development: consequences for patient educationMarc F D Baay, Veronique Verhoeven, Lieve Peremans, et al.
Cancers|December 23, 2022
Co-Targeting the EGFR and PI3K/Akt Pathway to Overcome Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma: What about Autophagy?Hannah Zaryouh, Jinthe Van Loenhout, Marc Peeters, et al.
Clinical Therapeutics|October 22, 2019
Cost-effectiveness of Molecular Profile Patient Selection for First-line Treatment of Recurrent/Metastatic Head and Neck CancerCarla Rognoni, Silvana Quaglini, Jan Baptist Vermorken, et al.
Medicinal Research Reviews|April 30, 2021
Recent insights in the PI3K/Akt pathway as a promising therapeutic target in combination with EGFR-targeting agents to treat head and neck squamous cell carcinomaHannah Zaryouh, Ines De Pauw, Hasan Baysal, et al.
Frontiers in Oncology|September 27, 2021
The Role of Akt in Acquired Cetuximab Resistant Head and Neck Squamous Cell Carcinoma: An <i>In Vitro</i> Study on a Novel Combination StrategyHannah Zaryouh, Ines De Pauw, Hasan Baysal, et al.
Frontiers in Immunology|September 24, 2021
The Right Partner in Crime: Unlocking the Potential of the Anti-EGFR Antibody Cetuximab <i>via</i> Combination With Natural Killer Cell Chartering Immunotherapeutic StrategiesHasan Baysal, Ines De Pauw, Hannah Zaryouh, et al.
Cancers|January 18, 2019
Overcoming Intrinsic and Acquired Cetuximab Resistance in RAS Wild-Type Colorectal Cancer: An In Vitro Study on the Expression of HER Receptors and the Potential of AfatinibInes De Pauw, Filip Lardon, Jolien Van den Bossche, et al.
Molecular Oncology|April 1, 2018
Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell linesInes De Pauw, Filip Lardon, Jolien Van den Bossche, et al.
Pageof 2